Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]

Bibliographic Details
Format:	Online
Language:	English
Published:	Dove Medical Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554400/

Similar Items

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
by: Hoggatt, Jonathan, et al.
Published: (2015)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia, Roberto, et al.
Published: (2016)

Review on lipegfilgrastim
by: Gasparic, Maja, et al.
Published: (2015)

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
by: Zou, Linglong, et al.
Published: (2016)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
by: Hashiguchi, Yasunori, et al.
Published: (2015)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
by: Vakkalanka, Bhanu, et al.
Published: (2011)

Microbial Translocation Contribute to Febrile Episodes in Adults with Chemotherapy-Induced Neutropenia
by: Wong, Michelle, et al.
Published: (2013)

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer
by: Ma, Rui-Min, et al.
Published: (2016)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
by: Ghidini, Michele, et al.
Published: (2016)

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
by: do Nascimento, Talita Garcia, et al.
Published: (2014)

Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
by: Lehmacher, W., et al.
Published: (2016)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
by: Bondarenko, Igor, et al.
Published: (2013)

Olanzapine-Induced Neutropenia
by: Malhotra, Kirti, et al.
Published: (2015)

Fluoxetine-induced neutropenia
by: Bavle, A.
Published: (2012)

Ipilimumab-Induced Neutropenia in Melanoma
by: Ban-Hoefen, Makiko, et al.
Published: (2016)

Developments in the management of febrile neutropenia
by: Pascoe, J
Published: (2011)

Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
by: Fortner, Barry V, et al.
Published: (2004)

Clozapine-Induced Febrile Neutropenia and Cellulitis
by: YAYLACI, Selcuk, et al.
Published: (2016)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli, Désirée, et al.
Published: (2016)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
by: Kukec, Renata Rezonja, et al.
Published: (2015)

Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
by: Riedel, Amy, et al.
Published: (2007)

Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma
by: Park, Jinyong, et al.
Published: (2012)

Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia
by: Trus, Michael, et al.
Published: (2013)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
by: Kukec Renata Rezonja, et al.
Published: (2015-06-01)

Predictive Factors For Neutropenia During Chemotherapy Treatment In Breast Cancer Patients
by: Ong, Chiew Wai
Published: (2017)

Terbinafine and Neutropenia
by: Yavaşoğlu, İrfan
Published: (2015)

Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
by: Mądry, Radosław, et al.
Published: (2016)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
by: Doaa Naeem, et al.
Published: (2018-08-01)

Dapsone-induced neutropenia with invasive pulmonary aspergillosis
by: Sabnis, Girish R., et al.
Published: (2012)

Filgrastim therapy in a child with neutropenia induced by linezolid
by: Hernández Segurado, Marta, et al.
Published: (2013)

Injectable Gold-Induced Hepatitis and Neutropenia in Rheumatoid Arthritis
by: Uhm, Wan-Sik, et al.
Published: (2000)

Outpatient management of febrile neutropenia in children with cancer
by: Ziino, Ottavio, et al.
Published: (2011)

Congenital neutropenia: diagnosis, molecular bases and patient management
by: Donadieu, Jean, et al.
Published: (2011)

Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients
by: Tian, Huan, et al.
Published: (2015)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
by: Weycker, Derek, et al.
Published: (2015)

Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
by: Nahon, Sophie, et al.
Published: (2015)

Evaluation of Bloodstream Infections During Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience
by: Piukovics, Klára, et al.
Published: (2015)

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
by: Weycker, Derek, et al.
Published: (2015)

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
by: LÓPEZ-POUSA, A, et al.
Published: (2010)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
by: Teofili, Luciana, et al.
Published: (2012)